- Home
- TYRA vs THRY Comparison
TYRA vs THRY Comparison
Compare TYRA & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- THRY
- Stock Information
- Founded
- TYRA 2018
- THRY 2003
- Country
- TYRA United States
- THRY United States
- Employees
- TYRA N/A
- THRY N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- THRY Industrial Machinery/Components
- Sector
- TYRA Health Care
- THRY Industrials
- Exchange
- TYRA Nasdaq
- THRY Nasdaq
- Market Cap
- TYRA 819.3M
- THRY 703.2M
- IPO Year
- TYRA 2021
- THRY 2020
- Fundamental
- Price
- TYRA $15.91
- THRY $16.22
- Analyst Decision
- TYRA Strong Buy
- THRY Strong Buy
- Analyst Count
- TYRA 6
- THRY 3
- Target Price
- TYRA $30.50
- THRY $24.33
- AVG Volume (30 Days)
- TYRA 261.4K
- THRY 629.2K
- Earning Date
- TYRA 03-18-2025
- THRY 02-20-2025
- Dividend Yield
- TYRA N/A
- THRY N/A
- EPS Growth
- TYRA N/A
- THRY N/A
- EPS
- TYRA N/A
- THRY N/A
- Revenue
- TYRA N/A
- THRY $873,723,000.00
- Revenue This Year
- TYRA N/A
- THRY N/A
- Revenue Next Year
- TYRA N/A
- THRY N/A
- P/E Ratio
- TYRA N/A
- THRY N/A
- Revenue Growth
- TYRA N/A
- THRY N/A
- 52 Week Low
- TYRA $12.34
- THRY $13.06
- 52 Week High
- TYRA $29.60
- THRY $26.42
- Technical
- Relative Strength Index (RSI)
- TYRA 52.83
- THRY 62.05
- Support Level
- TYRA $15.75
- THRY $13.93
- Resistance Level
- TYRA $17.27
- THRY $16.61
- Average True Range (ATR)
- TYRA 0.91
- THRY 0.67
- MACD
- TYRA 0.20
- THRY 0.21
- Stochastic Oscillator
- TYRA 65.99
- THRY 85.45
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About THRY Thryv Holdings Inc.
Thryv Holdings Inc provides software as service (SaaS) management tools and digital and print marketing tools to small and mid-sized businesses. The company operates in four reportable segments namely Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. It generates maximum revenue from the Thryv U.S. Marketing Services segment.